Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

키워드

참고문헌 (80)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
2. Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
3. Power DG, "Advanced gastric cancer--slow but steady progress", Cancer Treat Rev, 36, pp.384~392 (2010)
4. Sastre J, "Chemotherapy for gastric cancer", World J Gastroenterol, 12, pp.204~213 (2006)
5. Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
6. Stahl M, "Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction", J Clin Oncol, 27, pp.851~856 (2009)
7. Ychou M, "Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial", J Clin Oncol, 29, pp.1715~1721 (2011)
8. Juergens RA, "Combined modality therapy of esophageal cancer", J Natl Compr Canc Netw, 6, pp.851~860 (2008)
9. Haghighat P, "An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma", J Natl Compr Canc Netw, 6, pp.895~900 (2008)
10. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
11. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
12. Haenszel W, "Variation in incidence of and mortality from stomach cancer, with particular reference to the United States", J Natl Cancer Inst, 21, pp.213~262 (1958)
13. Haenszel W, "Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States", J Natl Cancer Inst, 40, pp.43~68 (1968)
14. Gomez SL, "Cancer incidence trends among Asian American populations in the United States, 1990-2008", J Natl Cancer Inst, 105, pp.1096~1110 (2013)
15. Chong ML, "Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation", Int J Cancer, 134, pp.1232~1238 (2014)
16. Pavlakis N, "Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE):A Multinational Placebo-Controlled Phase II Trial", J Clin Oncol, 34, pp.2728~2735 (2016)
17. Hecht JR, "Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma:TRIO-013", LOGiC--A randomized phase III trial, 2016, pp.34, 443~451
18. Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
19. Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
20. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
21. Okumura N, "PI3K", AKT, Adv Hematol, pp.2012, 2012[DOI]
22. Yuan TL, "PI3K pathway alterations in cancer: variations on a theme", Oncogene, 27, pp.5497~5510 (2008)
23. Cantley LC, "The phosphoinositide 3-kinase pathway", Science, 296, pp.1655~1657 (2002)
24. Hodgkinson CP, "Characterization of PDK2 activity against protein kinase B gamma", Biochemistry, 41, pp.10351~10359 (2002)
25. Manning BD, "AKT", PKB signaling: navigating downstream, 2007, pp.129, 1261~1274
26. Courtney KD, "The PI3K pathway as drug target in human cancer", J Clin Oncol, 28, pp.1075~1083 (2010)
27. Engelman JA, "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism", Nat Rev Genet, 7, pp.606~619 (2006)
28. Duronio V, "The life of a cell: apoptosis regulation by the PI3K", PKB pathway, 2008, pp.415, 333~344
29. Patel PH, "Targeting von Hippel-Lindau pathway in renal cell carcinoma", Clin Cancer Res, 12, pp.7215~7220 (2006)
30. Hay N, "Upstream and downstream of mTOR", Genes Dev, 18, pp.1926~1945 (2004)
31. Ortega-Molina A, "PTEN in cancer, metabolism, and aging", Trends Endocrinol Metab, 24, pp.184~189 (2013)
32. Klempner SJ, "What a tangled web we weave:emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway", Cancer Discov, 3, pp.1345~1354 (2013)
33. Markman B, "Status of PI3K inhibition and biomarker development in cancer therapeutics", Ann Oncol, 21, pp.683~691 (2010)
34. Samuels Y, "High frequency of mutations of the PIK3CA gene in human cancers", Science, 304, pp.554~ (2004)
35. Velho S, "The prevalence of PIK3CA mutations in gastric and colon cancer", Eur J Cancer, 41, pp.1649~1654 (2005)
36. Barbi S, "The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type", J Exp Clin Cancer Res, 29, pp.32~ (2010)
37. Sukawa Y, "HER2 expression and PI3K-Akt pathway alterations in gastric cancer", Digestion, 89, pp.12~17 (2014)
38. Wen YG, "Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K", AKT pathway, 2010, pp.24, 89~95
39. Han SY, "Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay", Cancer Res, 60, pp.3147~3151 (2000)
40. Carracedo A, "PTEN level in tumor suppression:how much is too little?", Cancer Res, 71, pp.629~633 (2011)
41. Nam SY, "Akt", PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis, 2003, pp.111, 1105~1113
42. Maroulakou IG, "Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2", neu and MMTV-polyoma middle T transgenic mice, 2007, pp.67, 167~177
43. Irie HY, "Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition", J Cell Biol, 171, pp.1023~1034 (2005)
44. Engelman JA, "Targeting PI3K signalling in cancer: opportunities, challenges and limitations", Nat Rev Cancer, 9, pp.550~562 (2009)
45. Li J, "The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere", J Transl Med, 11, pp.241~ (2013)
46. Thoreen CC, "An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1", J Biol Chem, 284, pp.8023~8032 (2009)
47. Shor B, "Targeting mTOR globally in cancer: thinking beyond rapamycin", Cell Cycle, 8, pp.3831~3837 (2009)
48. O’Reilly KE, "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt", Cancer Res, 66, pp.1500~1508 (2006)
49. Ramanathan RK, "A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005)", J Clin Oncol, 32(5(Suppl)) (2014)
50. Bang YJ, "JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma", J Clin Oncol, 32(5(Suppl)) (2014)
51. She QB, "Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling", PLoS One, 3, pp.e3065~ (2008)
52. Serra V, "NVP-BEZ235, a dual PI3K", mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations, 2008, pp.68, 8022~8030
53. Engelman JA, "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers", Nat Med, 14, pp.1351~1356 (2008)
54. Belmont PJ, "Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR", Sci Signal, 7, pp.ra107~ (2014)
55. Sheppard KE, "Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K", mTOR and RAS, Eur J Cancer, pp.2013, 49[DOI]
56. Zunder ER, "Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha", Cancer Cell, 14, pp.180~192 (2008)
57. Cejka D, "Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo", Cancer Biol Ther, 7, pp.1377~1385 (2008)
58. Fuereder T, "mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo", Cancer Lett, 296, pp.249~256 (2010)
59. Lee KH, "RAD001shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase", Cancer Lett, 299, pp.22~28 (2010)
60. Lang SA, "Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model", Int J Cancer, 120, pp.1803~1810 (2007)
61. Doi T, "Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer", J Clin Oncol, 28, pp.1904~1910 (2010)
62. Ohtsu A, "Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study", J Clin Oncol, 31, pp.3935~3943 (2013)
63. Meric-Bernstam F, "PIK3CA", PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors, 2012, pp.18, 1777~1789
64. O’Reilly T, "Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals", Transl Oncol, 3, pp.65~79 (2010)
65. Yoon DH, "Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum", Br J Cancer, 106, pp.1039~1044 (2012)
66. Wainberg ZA, "Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers", Cancer Chemother Pharmacol, 76, pp.61~67 (2015)
67. Park JH, "Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK-3CA mutation and pS6 overexpression", BMC Cancer, 15, pp.119~ (2015)
68. Lei Z, "Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil", Gastroenterology, 145, pp.554~565 (2013)
69. Mazumdar T, "A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma", Mol Cancer Ther, 13, pp.2738~2750 (2014)
70. Janku F, "Screening for PIK3CA mutations, PTEN loss, and RAS", RAF mutations in early-phase protocols with PI3K, J Clin Oncol, pp.2011, 29(Suppl)[DOI]
71. Britten CD, "PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types", Cancer Chemother Pharmacol, 71, pp.1395~1409 (2013)
72. Ma L, "Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis", Cell, 121, pp.179~193 (2005)
73. Garrett JT, "Transcriptional and posttranslational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase", Proc Natl Acad Sci U S A, 108, pp.5021~5026 (2011)
74. Chandarlapaty S, "AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity", Cancer Cell, 19, pp.58~71 (2011)
75. Tenbaum SP, "β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer", Nat Med, 18, pp.892~901 (2012)
76. Serra V, "PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer", Oncogene, 30, pp.2547~2557 (2011)
77. Bedard P, "A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1", 2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors, 2012, pp.30(Suppl), ~
78. LoRusso P, "A first-in-human phase Ib study to evaluate and c.w.t.p.-P. K.i.G.-. the MEK inhibitor GDC-0973, in patients with advanced solid tumors", J Clin Oncol, 30(Suppl) (2012)
79. Shimizu T, "The clinical effect of the dual-targeting strategy involving PI3K", AKT, MEK, pp.ERK pathways in patients with advanced cancer, Clin Cancer Res[DOI]
80. Ali SM, "Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies", Oncologist, 20, pp.499~507 (2015)

관련 논문AI추천